
Sign up to save your podcasts
Or
Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes
5
11 ratings
Following the approval of Aflibercept 8mg, clinicians in Europe now have 5 anti-VEGF treatments to choose from, not to mention biosimilars. How should we treat patients with so many options open to us? Sandrine Zweifel (Switzerland) and Stela Vujosevic (Italy) compare notes
43 Listeners
99 Listeners
17 Listeners
1 Listeners
8 Listeners
33 Listeners
51 Listeners
10 Listeners
17 Listeners
16 Listeners
16 Listeners
989 Listeners
0 Listeners